Summary

* Safety assessment of cosmetic formulations using sCD83-based MAL-838 completed successfully

* INCI name assigned and listing in the European CosIng database obtained

* All upcoming 8T3 cosmetic products have been certified as microbiome-friendly

Erlangen, Germany, August 20, 2025 – Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, today announced the successful completion of multiple important steps in the development and regulatory validation of MAL838. MAL-838 builds the foundation for the companys upcoming hormone-free 8T3 product line targeting hair growth and is derived from the human soluble protein sCD83. Laboratory studies have shown that sCD83 is able to stimulate hair growth and induce signaling pathways for hair growth including in human tissue samples and induce new hair follicles in several model systems.

As part of Mallia Aesthetics preparations for market launch in the fourth quarter of this year, a comprehensive safety assessment of the formulations of all planned 8T3 products has been successfully completed in accordance with the European Cosmetics Regulation EU 1223/2009. Extensive in vitro and in silico tests by an independent laboratory have demonstrated the safety of MAL-838 as a cosmetic ingredient. The safety reports now confirm that MAL-838 and the formulations of all planned 8T3 products can be used safely, which paves the way for commercialization of the cosmetics.

In parallel, MAL838 has now been officially listed in the European CosIng database (Cosmetic Ingredients Database), the EUs authoritative registry of cosmetic ingredients, which further establishes its regulatory compliance and market readiness. The ingredient has also been assigned a dedicated

Source:

Read More